Table 1.
Common dimensions in intervention ensembles
| |
Examples |
Cetuximab |
Belimumab |
Gene transfer for AID-SCID |
|---|---|---|---|---|
| Treatment dimension | ||||
| Dose |
mg/kg; cells; vector particles… |
250 mg/m2 |
10 mg/kg |
≥8 × 10^6 cells |
| Schedule |
Daily; 4× weekly w/2 wk holidays… |
Weekly until disease progression |
3× @ 2-wk intervals; 4-wk intervals after |
|
| Administration/target |
Infusion; oral; intratumoral… |
Intravenous infusion |
Intravenous infusion |
Intravenous infusion |
| Co-intervention |
Radiotherapy; immunosuppresion… |
|
Standard of care |
Non-myeloablative conditioning |
| Risk mitigation |
Cardiac monitoring; liver enzymes… |
Serum electrolytes monitoring |
Monitor patients for hypersensitivity |
|
| Timing delivery |
Symptom onset; 12 h after event… |
After irinotecan or oxaliplatin failure |
|
3 weeks after stopping PEG-ADA |
|
Population dimensions | ||||
| Diagnostic criteria |
Marker positivity; diagnostic score… |
KRAS mutation in codon 12 or 13 |
α-nuclear Ab titer ≥ 1:80 and/or α-dsDNA |
|
| Contraindications |
Concurrent infection; clothing disorder… |
|
Prior anaphylaxis to belimumab |
Neutralizing Abs to vector (AAV8) |
| Indications |
Disease; injury; at-risk population… |
Metastatic colorectal cancer |
Active systemic lupus erythematosus (SLE) |
ADA-SCID |
| Age |
|
Adults |
Non-geriatric adults |
Children |
|
Outcome dimensions | ||||
| Endpoint |
Change on scale; time to event… |
Survival |
SLE responder index |
Immune system reconstitution |
| Duration | Short term; ‘long term’ remission… | 1 year | Permanent | |